Nothing Special   »   [go: up one dir, main page]

DE69835294D1 - Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps) - Google Patents

Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)

Info

Publication number
DE69835294D1
DE69835294D1 DE69835294T DE69835294T DE69835294D1 DE 69835294 D1 DE69835294 D1 DE 69835294D1 DE 69835294 T DE69835294 T DE 69835294T DE 69835294 T DE69835294 T DE 69835294T DE 69835294 D1 DE69835294 D1 DE 69835294D1
Authority
DE
Germany
Prior art keywords
vlps
tennels
disassembly
reproduction
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835294T
Other languages
English (en)
Other versions
DE69835294T2 (de
DE122007000015I1 (de
Inventor
P Mccarthy
Joann Suzich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of DE69835294D1 publication Critical patent/DE69835294D1/de
Application granted granted Critical
Publication of DE69835294T2 publication Critical patent/DE69835294T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
    • Y10S977/803Containing biological material in its interior
    • Y10S977/804Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69835294T 1997-09-05 1998-08-19 Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps) Expired - Lifetime DE69835294T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
US923997 1997-09-05
PCT/US1998/016464 WO1999013056A1 (en) 1997-09-05 1998-08-19 IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)

Publications (2)

Publication Number Publication Date
DE69835294D1 true DE69835294D1 (de) 2006-08-31
DE69835294T2 DE69835294T2 (de) 2007-07-26

Family

ID=25449564

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69835294T Expired - Lifetime DE69835294T2 (de) 1997-09-05 1998-08-19 Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
DE1998635294 Pending DE122007000015I1 (de) 1997-09-05 1998-08-19 Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virus-ähnlichen Teilchen (vlps)
DE200712000015 Active DE122007000015I2 (de) 1997-09-05 1998-08-19 Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virusähnlichen Teilchen (vlps)

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE1998635294 Pending DE122007000015I1 (de) 1997-09-05 1998-08-19 Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virus-ähnlichen Teilchen (vlps)
DE200712000015 Active DE122007000015I2 (de) 1997-09-05 1998-08-19 Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virusähnlichen Teilchen (vlps)

Country Status (16)

Country Link
US (2) US6261765B1 (de)
EP (2) EP1015561B1 (de)
JP (2) JP4199416B2 (de)
AT (1) ATE333501T1 (de)
AU (1) AU742409B2 (de)
CA (1) CA2302545C (de)
CY (2) CY1107987T1 (de)
DE (3) DE69835294T2 (de)
DK (1) DK1015561T3 (de)
ES (2) ES2268787T3 (de)
FR (1) FR07C0012I2 (de)
HK (1) HK1030797A1 (de)
LU (1) LU91314I2 (de)
NL (1) NL300264I2 (de)
PT (1) PT1015561E (de)
WO (1) WO1999013056A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AU732125B2 (en) * 1996-07-17 2001-04-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious papillomavirus pseudoviral particles
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
CA2394052C (en) * 1999-12-09 2015-03-17 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
EP1305039B1 (de) * 2000-07-06 2008-12-31 Georgetown University Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
AU2001294565A1 (en) * 2000-09-18 2002-04-02 Med Immune, Inc. In vitro assay for measuring the immunogenicity of a vaccine
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
WO2003103605A2 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
JP5475939B2 (ja) 2002-12-20 2014-04-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Hpv−16およびhpv−18l1vlpワクチン
JP4734608B2 (ja) 2004-07-01 2011-07-27 国立大学法人東京工業大学 生理的条件下でのウイルス粒子様構造体及びその形成方法
WO2007053188A2 (en) * 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
SI2145189T1 (sl) 2007-05-08 2016-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papilomavirusni psevdovirusi za detekcijo in terapijo tumorjev
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
WO2010149752A2 (en) 2009-06-25 2010-12-29 Glaxosmithline Biologicals S.A. Novel compositions
US20120164710A1 (en) * 2009-07-03 2012-06-28 Yuan Yuan Fan Method of preparation of a biological particulate structure
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP3517130B1 (de) 2013-09-18 2022-03-30 Aura Biosciences, Inc. Methode zur herstellung photosensitiver moleküle
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
KR101825996B1 (ko) * 2014-12-26 2018-02-09 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral
EP3368656A4 (de) 2015-10-30 2019-07-17 The United States of America, as represented by the secretary, Department of Health and Human Services Gezielte krebstherapie
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
CA3081757A1 (en) 2017-11-06 2019-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer treatment utilizing pre-existing microbial immunity
EP3710468A1 (de) 2017-11-14 2020-09-23 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Nicht-menschliche papillomaviren zum gentransfer in vitro und in vivo
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたvlpワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
EP1700911A1 (de) 2006-09-13
JP2009057377A (ja) 2009-03-19
CY1107987T1 (el) 2011-04-06
EP1015561B1 (de) 2006-07-19
CA2302545C (en) 2012-04-03
LU91314I2 (fr) 2007-04-23
US6261765B1 (en) 2001-07-17
CA2302545A1 (en) 1999-03-18
HK1030797A1 (en) 2001-05-18
FR07C0012I2 (fr) 2007-10-26
WO1999013056A1 (en) 1999-03-18
EP1015561A1 (de) 2000-07-05
NL300264I1 (nl) 2007-05-01
NL300264I2 (nl) 2008-06-02
DK1015561T3 (da) 2006-11-13
CY2007007I1 (el) 2009-11-04
DE69835294T2 (de) 2007-07-26
DE122007000015I1 (de) 2007-05-24
EP1700911B1 (de) 2016-04-06
DE122007000015I2 (de) 2008-01-24
PT1015561E (pt) 2006-11-30
JP2001515922A (ja) 2001-09-25
US6416945B1 (en) 2002-07-09
AU742409B2 (en) 2002-01-03
LU91314I9 (de) 2019-01-30
JP4199416B2 (ja) 2008-12-17
JP4486142B2 (ja) 2010-06-23
AU9015498A (en) 1999-03-29
ES2572628T3 (es) 2016-06-01
ATE333501T1 (de) 2006-08-15
ES2268787T3 (es) 2007-03-16
FR07C0012I1 (de) 2007-03-30
CY2007007I2 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
ATE296111T1 (de) Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
GEP20084431B (en) Papilloma virus vaccine
PL317234A1 (en) Vaccines against papilloma virus
JP2005270111A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
DK0698668T3 (da) Fremgangsmåde til fremstilling af L-leucin
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
ATE489106T1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: HUMANES PAPILLOMVIRUS-TYPE 6 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 11 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 16 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYPE 18 L1-PROTEIN; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 015

Filing date: 20070221

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: HUMANES PAPILLOMVIRUS-TYPE 6 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 11 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 16 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYPE 18 L1-PROTEIN; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 015

Filing date: 20070221

8364 No opposition during term of opposition
V457 Spc granted

Free format text: PRODUCT NAME: HUMANES PAPILLOMVIRUS-TYPE 6 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 11 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYP 16 L1-PROTEIN, HUMANES PAPILLOMVIRUS-TYPE 18 L1-PROTEIN; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 015

Filing date: 20070221